Piper Sandler analyst Jason Bednar lowered the firm’s price target on Pulmonx (LUNG) to $9 from $10 and keeps an Overweight rating on the shares. The firm notes the company reported Q1 results, including revenue of $22.5M/+20% year-over-year that finished ahead of Street’s $22M, with revenue growth driven by outside U.S. outperformance, while adjusted EBITDA and cash burn continue to trend in the right direction.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUNG:
- Pulmonx price target lowered to $15 from $16 at Canaccord
- Pulmonx Positioned for Sustained Growth with Strong Q1 Performance and Strategic Initiatives
- Pulmonx Corporation Reports Strong Q1 2025 Results
- Pulmonx reports Q1 EPS (36c), consensus (40c)
- Pulmonx backs FY25 revenue view $96M-$98M, consensus $96.98M